DE2516274C2 - Verfahren zum Herstellen eines abgeschwächten Zytomegalie-Virus-Impfstoffes - Google Patents

Verfahren zum Herstellen eines abgeschwächten Zytomegalie-Virus-Impfstoffes

Info

Publication number
DE2516274C2
DE2516274C2 DE2516274A DE2516274A DE2516274C2 DE 2516274 C2 DE2516274 C2 DE 2516274C2 DE 2516274 A DE2516274 A DE 2516274A DE 2516274 A DE2516274 A DE 2516274A DE 2516274 C2 DE2516274 C2 DE 2516274C2
Authority
DE
Germany
Prior art keywords
virus
cmv
attenuated
vaccine
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE2516274A
Other languages
German (de)
English (en)
Other versions
DE2516274A1 (de
Inventor
Stanley A. Philadelphia Pa. Plotkin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The Wistar Institute
Original Assignee
The Wistar Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Wistar Institute filed Critical The Wistar Institute
Publication of DE2516274A1 publication Critical patent/DE2516274A1/de
Application granted granted Critical
Publication of DE2516274C2 publication Critical patent/DE2516274C2/de
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE2516274A 1974-04-15 1975-04-14 Verfahren zum Herstellen eines abgeschwächten Zytomegalie-Virus-Impfstoffes Expired DE2516274C2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/460,951 US3959466A (en) 1974-04-15 1974-04-15 Highly attenuated cytomegalovirus vaccine and production thereof

Publications (2)

Publication Number Publication Date
DE2516274A1 DE2516274A1 (de) 1975-10-23
DE2516274C2 true DE2516274C2 (de) 1986-10-30

Family

ID=23830680

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2516274A Expired DE2516274C2 (de) 1974-04-15 1975-04-14 Verfahren zum Herstellen eines abgeschwächten Zytomegalie-Virus-Impfstoffes

Country Status (11)

Country Link
US (1) US3959466A (enExample)
JP (1) JPS58406B2 (enExample)
BE (1) BE827572A (enExample)
CA (1) CA1045546A (enExample)
CH (1) CH617588A5 (enExample)
DE (1) DE2516274C2 (enExample)
FR (1) FR2267117B1 (enExample)
GB (1) GB1501724A (enExample)
NL (1) NL7504480A (enExample)
SE (1) SE7504221L (enExample)
ZA (1) ZA751949B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4058598A (en) * 1974-10-18 1977-11-15 Harold Stern Cytomegalovirus attenuation method and vaccine
AU532186B2 (en) * 1978-07-21 1983-09-22 Merck & Co., Inc. Herpes virus vaccine
US6242567B1 (en) 1984-07-27 2001-06-05 City Of Hope Method for detection and prevention of human cytomegalovirus infection
US6133433A (en) * 1984-07-27 2000-10-17 City Of Hope Method for detection and prevention of human cytomegalovirus infection
US5194256A (en) * 1984-08-21 1993-03-16 The Board Of Trustees Of The Leland Sanford Junior University Purified human cytomegalovirus protein
US4689225A (en) * 1984-11-02 1987-08-25 Institut Merieux Vaccine for cytomegalovirus
US5126130A (en) * 1986-11-24 1992-06-30 The Childrens Hospital Incorporated Monoclonal antibodies reactive with specific antigenic sites on human cytomegalovirus glycoprotein a
US5248768A (en) * 1986-11-24 1993-09-28 The Children's Hospital, Incorporated Immunogenic glycoproteins of human cytomegalovirus
US5153311A (en) * 1986-11-24 1992-10-06 The Children's Hospital, Incorporated Immunogenic glycoproteins of human cytomegalovirus gCII
EP0277773A1 (en) * 1987-01-30 1988-08-10 The Board Of Trustees Of The Leland Stanford Junior University Hybrid cytomegalovirus (CMV) and vaccine
US5591439A (en) * 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
US5552143A (en) * 1989-03-24 1996-09-03 The Wistar Institute Of Anatomy & Biology Recombinant cytomegalovirus vaccine
US5180813A (en) * 1989-03-24 1993-01-19 University Of Iowa Research Foundation Early envelope glycoprotein of human cytomegalovirus (hmcv) and monoclonal antibodies to the glycoproteins
US6448389B1 (en) 1996-04-23 2002-09-10 The Wistar Institute Of Anatomy And Biology Human cytomegalovirus DNA constructs and uses therefor
US6835383B2 (en) * 2000-03-23 2004-12-28 City Of Hope Protein kinase deficient, immunologically active CMVpp65 mutants
EP1178111A1 (en) * 2000-08-03 2002-02-06 Lohmann Animal Health GmbH & Co. KG Vaccination against host cell-associated herpesviruses
US6692954B1 (en) 2000-11-03 2004-02-17 The Scripps Research Institute Generation of human cytomegalovirus yeast artificial chromosome recombinants
US9439960B2 (en) 2007-10-10 2016-09-13 The Trustees Of Princeton University Cytomegalovirus vaccines and methods of production
WO2021014398A1 (en) 2019-07-23 2021-01-28 University Of Rijeka Faculty Of Medicine Integrated human cytomegalovirus / glioblastoma vaccine

Also Published As

Publication number Publication date
CH617588A5 (enExample) 1980-06-13
FR2267117A1 (enExample) 1975-11-07
ZA751949B (en) 1976-02-25
SE7504221L (sv) 1975-12-22
JPS58406B2 (ja) 1983-01-06
NL7504480A (nl) 1975-10-17
BE827572A (fr) 1975-10-06
DE2516274A1 (de) 1975-10-23
JPS5115612A (enExample) 1976-02-07
CA1045546A (en) 1979-01-02
GB1501724A (en) 1978-02-22
FR2267117B1 (enExample) 1978-11-24
US3959466A (en) 1976-05-25
AU8002475A (en) 1976-10-14

Similar Documents

Publication Publication Date Title
DE2516274A1 (de) Stark abgeschaechter megalozytenvirusimpfstoff und dessen herstellung
DE2851928C2 (enExample)
DE1617940C2 (de) Verfahren zur Gewinnung eines für die Züchtung von Viren geeigneten Zellstammes
DE2708668A1 (de) Nd-impfstoff und verfahren zu seiner herstellung
DE2713371C2 (enExample)
CH622702A5 (enExample)
CH658192A5 (de) Tollwut-impfstoff und verfahren zu seiner herstellung.
DE2553998C2 (de) Mumpsvaccin und Verfahren zu seiner Herstellung
DE2425997A1 (de) Verfahren zur herstellung von abgeschwaechtem katzenfiebervakzin
DE69328341T2 (de) Impfstoff gegen infektiöse Bursal-Krankheit
DE2739439C2 (enExample)
DE69014974T2 (de) Impfstoff gegen Hundecoronavirus.
DE2058645C2 (de) Verfahren zur Herstellung eines stark abgeschwächten Newcastle-Disease-Virus-Lebendimpfstoffs
DE3878982T2 (de) Abgeschwaechtes virus und impfstoffe davon zur verwendung gegen infektionen bei gefluegel, verursacht durch truthahn-rhinotracheitis-virus.
DE2805311A1 (de) Respiratorische synzytial-vakzine
DE1692043C3 (de) Rhinopneumonitis-Vaccine und Verfahren zu deren Herstellung
DE2057544B2 (de) Impfstoff gegen ein neonatales Kälberdiarrhoevirus, Verfahren zu seiner Herstellung und seine Verwendung
DE2328579A1 (de) Varicella-vaccine
DE2162013C3 (de) Tollwut-Lebendimpfstoff, Verfahren zu seiner Herstellung nd seine Verwendung bei der Bekämpfung von Tollwut
DE2132911C2 (de) Verfahren zum Herstellen eines stark abgeschwächte Rötelviren enthaltenden Impfstoffs
DE3779444T2 (de) Impfstoff gegen herpes simplex.
DE3009064A1 (de) Verfahren zur herstellung eines tollwutimpfstoffes und danach erhaltener impfstoff
DE1021128B (de) Verfahren zur Herstellung eines Impfstoffes gegen die Rhinotracheitis der Rinder
DE2129777C3 (de) Verfahren zur Herstellung eines stark ageschwächte Rötelviren enthaltenden Impfstoffes
DE3136430A1 (de) Orfvirus, verfahren zur herstellung eines orfvirus-lebendimpfstoffes und seine verwendung zur parenteralen schutzimpfung gegen die orf-infektionen der schafe und ziegen

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
8128 New person/name/address of the agent

Representative=s name: SCHOENWALD, K., DR.-ING. FUES, J., DIPL.-CHEM. DR.

D2 Grant after examination
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee